In patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, the current status of drug development in CF is discussed and future directions highlighted. Methods for pre-clinical testing of drugs with potential activity in CF patients including relevant animal models are described. Study design options for phase II and phase III studies involving CF patients are provided, including required patient numbers, safety issues and surrogate end point parameters for drugs, tested for different disease manifestations. Finally, regulatory issues for licensing new therapies for CF patients are discussed, including new directives of the European Union and the structure of
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF...
The European Pediatric Pharmaceutical Legislation wants children to benefit more from pharmaceutical...
AbstractIn patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, th...
In this article we analyse the current authorised treatments and trends in early drug development fo...
In this article we analyse the current authorised treatments and trends in early drug development fo...
Abstract Objectives Study of currently approved drugs and exploration of future clinical development...
The first regulatory approval for a drug developed specifically for cystic fibrosis (CF) occurred in...
Whilst substantial progress has been made in the treatment of cystic fibrosis, the disease still car...
Introduction: Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems. Research a...
The life expectancy of people with cystic fibrosis (CF), a lethal inherited disease, has been greatl...
Cystic fibrosis (CF) is an autosomal recessive disorder due to mutations in the Cystic Fibrosis Tran...
Recent strides towards precision medicine in Cystic Fibrosis (CF) have been made possible by patient...
A workshop was held by the PIPE-CF strategic research centre to consider preclinical testing of anti...
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects o...
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF...
The European Pediatric Pharmaceutical Legislation wants children to benefit more from pharmaceutical...
AbstractIn patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, th...
In this article we analyse the current authorised treatments and trends in early drug development fo...
In this article we analyse the current authorised treatments and trends in early drug development fo...
Abstract Objectives Study of currently approved drugs and exploration of future clinical development...
The first regulatory approval for a drug developed specifically for cystic fibrosis (CF) occurred in...
Whilst substantial progress has been made in the treatment of cystic fibrosis, the disease still car...
Introduction: Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems. Research a...
The life expectancy of people with cystic fibrosis (CF), a lethal inherited disease, has been greatl...
Cystic fibrosis (CF) is an autosomal recessive disorder due to mutations in the Cystic Fibrosis Tran...
Recent strides towards precision medicine in Cystic Fibrosis (CF) have been made possible by patient...
A workshop was held by the PIPE-CF strategic research centre to consider preclinical testing of anti...
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects o...
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF...
The European Pediatric Pharmaceutical Legislation wants children to benefit more from pharmaceutical...